Biomarin

Update: BioMarin To Acquire Prosensa Holding N.V.
Seeking Alpha
Thu, 01/15/15 - 12:03 pm
Biomarin
Prosensa
M&A
Shire’s Next Targets Could Be on This List: Real M&A
Bloomberg
Wed, 01/14/15 - 10:00 am
Shire
M&A
PTC Therapeutics
SynaGeva BioPharma
Retrophin
Ultragenyx
Vertex Pharmaceuticals
Biomarin
BioMarin CEO Sees Big Future For Prosensa Drug
Investors.com
Wed, 12/24/14 - 08:58 am
Biomarin
Prosensa
drisapersen
Duchenne Muscular Dystrophy
J.P. Morgan's 6 Top Biotech and Pharmaceuticals Stocks to Buy in 2015
TheStreet.com
Mon, 12/22/14 - 09:47 am
Alexion
Biomarin
Bristol-Myers Squibb
Jazz Pharmaceuticals
Valeant Pharmaceuticals
Illumina
BioMarin Expands Reach By Buying Prosensa for Up to $840 Million
TheStreet.com
Mon, 11/24/14 - 09:42 am
Biomarin
Prosensa
M&A
The top 10 most expensive drugs of 2013
Fierce Pharma
Tue, 10/14/14 - 10:05 am
drug pricing
Soliris
Alexion
Naglazyme
Biomarin
Kalydeco
Vertex
Cinryze
Shire
Sprycel
Bristol-Myers Squibb
Pomalyst
Celgene
Xyrem
Jazz Pharmaceuticals
Erbitux
Merck KGaA
Revlimid
Questcor
Mallinckrodt
H.P. Acthar Gel
5 Orphan Drug Biotech Stocks to Buy With Big Upside Potential
24/7 Wall St
Thu, 09/25/14 - 09:21 am
orphan drugs
Alnylam
Biomarin
Alexion
Isis Pharmaceuticals
Vertex Pharmaceuticals
BioMarin's Q1 Loss Shrinks 79% Due to Higher Rare Disease Drug Sales
Motley Fool
Fri, 05/2/14 - 08:38 am
Biomarin
earnings
Loss at BioMarin Narrower Than Expected
Yahoo/Zacks.com
Thu, 02/27/14 - 11:26 am
earnings
Biomarin
BioMarin and its patient coaches are ready to roll on Vimizim launch
Fierce Pharma
Mon, 02/17/14 - 07:48 pm
Biomarin
Vimizim
drug launches
FDA approves BioMarin's genetic disorder drug Vimizim
Yahoo/Reuters
Fri, 02/14/14 - 06:29 pm
Biomarin
FDA
Vimizim
Morquio A Syndrome
This Week in Biotech: Clinical Success, Plus Wheeling and Dealing
Motley Fool
Sun, 01/26/14 - 10:46 am
BioDelivery Sciences
Endo Health Solutions
Karyopharm Therapeutics
Repligen
Biomarin
Ariad Pharmaceuticals
Eli Lilly
GSK
Shire
Drugmakers see innovation justifying further price rises
Reuters
Fri, 01/17/14 - 05:44 pm
innovation
Biomarin
Roche
Herceptin
Biogen Idec
UBS Has Nine Biotech Buyout and Merger Candidates
24/7 Wall St
Tue, 01/14/14 - 09:07 am
biotech
M&A
Alexion
Biomarin
Incyte
Medivation
Idenix
Insmed
InterMune
Puma Biotechnology
Vertex Pharmaceuticals
What’s Next for Biotech?
Barron's
Fri, 01/10/14 - 06:47 pm
Celgene
Alexion
Incyte
Biomarin
22 Biotech Stock Predictions for 2014
TheStreet.com
Mon, 01/6/14 - 09:47 am
biotech
Vertex Pharmaceuticals
Orexigen
Retrophin
Valeant Pharmaceuticals
Questcor
Biomarin
Merck
NeoStem
Amgen
Gilead Sciences
Vanda
Keryx
Peregrine Pharmaceuticals
CelSci
Regeneron
Cempra
Dendreon
Clovis Oncology
Halozyme
NPS Pharmaceuticals
What Does the ViroPharma Buyout Mean for BioMarin?
Motley Fool
Mon, 12/30/13 - 12:06 pm
ViroPharma
M&A
Biomarin
Shire
3 Lessons Big Pharma Learned From BioMarin in 2013
Motley Fool
Sun, 12/8/13 - 12:08 pm
Biomarin
Galena: A Pipeline Rich For Investors
Seeking Alpha
Mon, 12/2/13 - 08:29 am
Galena Biopharma
INSYS Therapeutics
Biomarin
NeuVax
2014 FDA Drug Approval Decision Calendar
TheStreet.com
Wed, 11/27/13 - 08:39 am
FDA
drug approvals
GSK
Gilead
Theravance
Auxilium
Amarin
Bristol-Myers Squibb
Biogen Idec
Pozen
Vanda
Chelsea Therapeutics
pSivida
Alimera
United Therapeutics
Biomarin
JNJ
Pharmacyclics
Celgene
MannKind
Santarus
AstraZeneca
Durata Therapeutics
Eli Lilly
Omeros
BioDelivery Sciences
Anacor
Keryx
Cubist Pharmaceuticals
Nektar

Pages